An expert in cannabinoid-based medicine, Dr MacCallum is an internist and cannabinoid clinician as well as a researcher and instructor in the department of medicine at the University of British Columbia. She is also an associate member of the University of British Columbia’s palliative care department, as well as the medical director at Greenleaf Medical Clinic, where she has developed cannabinoid treatment plans for more than 3,000 patients across Canada.
Her recent publication, Practical Consideration for Medical Cannabis Administration and Dosing, offers guidance on medical cannabis dosing.
“Dr MacCallum’s vast experience in cannabinoid research will be invaluable to TGOD,” said Brian Athaide, CEO of The Green Organic Dutchman in a statement.
“She has been recognized by her peers in the medical industry as an expert in medical cannabis with a focus on dosing, which will be critical as we prepare to launch a suite of multi-dose products under the recently announced responsible Regulation of Edible Cannabis Products in Canada,” Athaide added.
Dessureault, meanwhile, hails from the pharmaceutical industry. He has worked as a global marketing division head for Novartis and as the president and general manager of Valeant Pharmaceuticals International Inc (NYSE:VRX) as well as a vice-president at Bristol Myers-Squibb. During Dessureault's time at Valeant, he led all Canadian commercial units, including research and development and international manufacturing and technical operations
"As we advance the research and development arms of our Company, including our beverage science and research division, Jacques' experience will be critical to launching new novel and innovative product lines," said Athaide.
The Green Organic Dutchman is a research and development company licensed by Canadian regulators to cultivate medical cannabis. It has cultivation facilities in Ontario, Quebec and Jamaica.
It has organic cannabis operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America as well as the recreational cannabis market in Canada. The company’s products are tested in labs to ensure their safety and consistency.
Shares in The Green Organic Dutchman closed down 1.9% to finish at C$2.54 on Monday.
Contact Ellen Kelleher at email@example.com